These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34659898)

  • 21. The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.
    Textor S; Bossler F; Henrich KO; Gartlgruber M; Pollmann J; Fiegler N; Arnold A; Westermann F; Waldburger N; Breuhahn K; Golfier S; Witzens-Harig M; Cerwenka A
    Oncoimmunology; 2016 Jul; 5(7):e1116674. PubMed ID: 27622013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of the Significant Genes Regulated by Estrogen Receptor in Estrogen Receptor-Positive Breast Cancer and Their Expression Pattern Changes When Tamoxifen or Fulvestrant Resistance Occurs.
    Cheng R; Qi L; Kong X; Wang Z; Fang Y; Wang J
    Front Genet; 2020; 11():538734. PubMed ID: 33133141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can estrogen receptor overexpression in normal tissues due to previous estrogen deprivation explain the fulvestrant efficacy in breast cancer therapy?
    Kurbel S
    Med Hypotheses; 2012 Dec; 79(6):869-71. PubMed ID: 23062772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma.
    Mantovani S; Oliviero B; Lombardi A; Varchetta S; Mele D; Sangiovanni A; Rossi G; Donadon M; Torzilli G; Soldani C; Porta C; Pedrazzoli P; Chiellino S; Santambrogio R; Opocher E; Maestri M; Bernuzzi S; Rossello A; Clément S; De Vito C; Rubbia-Brandt L; Negro F; Mondelli MU
    Hepatology; 2019 Mar; 69(3):1165-1179. PubMed ID: 30153337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer.
    Yang S; Cao B; Zhou G; Zhu L; Wang L; Zhang L; Kwok HF; Zhang Z; Zhao Q
    Front Pharmacol; 2020; 11():1089. PubMed ID: 32848731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells.
    Nukatsuka M; Saito H; Noguchi S; Takechi T
    In Vivo; 2019; 33(5):1439-1445. PubMed ID: 31471390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
    Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
    Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
    Liu H; Cheng D; Weichel AK; Osipo C; Wing LK; Chen B; Louis TE; Jordan VC
    Int J Oncol; 2006 Nov; 29(5):1237-46. PubMed ID: 17016657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.
    Giessrigl B; Schmidt WM; Kalipciyan M; Jeitler M; Bilban M; Gollinger M; Krieger S; Jäger W; Mader RM; Krupitza G
    Br J Cancer; 2013 Nov; 109(10):2751-62. PubMed ID: 24169358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.
    Zou Y; Bao J; Pan X; Lu Y; Liao S; Wang X; Wang G; Lin D
    PLoS One; 2015; 10(8):e0134568. PubMed ID: 26241657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
    Fiegler N; Textor S; Arnold A; Rölle A; Oehme I; Breuhahn K; Moldenhauer G; Witzens-Harig M; Cerwenka A
    Blood; 2013 Aug; 122(5):684-93. PubMed ID: 23801635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
    Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.
    Xu X; Narni-Mancinelli E; Cantoni C; Li Y; Guia S; Gauthier L; Chen Q; Moretta A; Vély F; Eisenstein E; Rangarajan S; Vivier E; Mariuzza RA
    J Mol Biol; 2016 Nov; 428(22):4457-4466. PubMed ID: 27663271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.
    Cao G; Wang J; Zheng X; Wei H; Tian Z; Sun R
    J Biol Chem; 2015 Dec; 290(50):29964-73. PubMed ID: 26472927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fulvestrant-Mediated Attenuation of the Innate Immune Response Decreases ER
    Abrahamsson A; Rodriguez GV; Dabrosin C
    Cancer Res; 2020 Oct; 80(20):4487-4499. PubMed ID: 32855207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
    Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
    Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
    Kornblum N; Zhao F; Manola J; Klein P; Ramaswamy B; Brufsky A; Stella PJ; Burnette B; Telli M; Makower DF; Cheema P; Truica CI; Wolff AC; Soori GS; Haley B; Wassenaar TR; Goldstein LJ; Miller KD; Sparano JA
    J Clin Oncol; 2018 Jun; 36(16):1556-1563. PubMed ID: 29664714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.